Ohmeda's Revex will launch in late May/early June; color-coded for post-op or opioid overdose reversal.
Executive Summary
OHMEDA REVEX LAUNCH TO OCCUR IN LATE MAY/EARLY JUNE to anesthesiology and emergency medical professionals, the Liberty Corner, N.J.-based subsidiary of the British BOC Group announced April 27. FDA approved NDA 20-459 (nalmefene HCl injection) April 17 for the reversal of opioid drug effects, including postoperative respiratory depression, induced by either natural or synthetic opioids, and for the management of known or suspected opioid overdose ("The Pink Sheet" April 24, In Brief).